Merck & Co., Inc. (MRK) — closed signal from February 1, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on May 2, 2026.
Predicted vs. what happened
What happened
Reached its target in 4 days.
The thesis — published February 1, 2026
Merck has an upcoming earnings report in the Feb 2-6 window that could change what investors expect over the next few months. Healthcare can attract safer money if markets get nervous, but the stock can move sharply after results. Buying near the stated range instead of chasing a pre-earnings jump helps keep your potential loss limited.
Primary drivers
- Earnings the week of Feb 2 can change company outlook quickly
- Healthcare can draw safer money when markets get shaky
- News about the drug pipeline and cancer treatments can lift sentiment
- Strong event risk means sticking to disciplined entry prices
How it played out
MRK: target reached in 4 days
Lyra published MRK at 110.27 on 2026-02-01, with 11% expected growth and a 122.4 target for the short-term window. The thesis pointed to earnings in the week of Feb 2, demand for healthcare when markets got shaky, pipeline and cancer-treatment news, and disciplined entry prices around 108 to 112.
Inside the window from 2026-02-01 to 2026-05-02, MRK reached the target in 4 days. It later peaked at 125.14 on 2026-02-25, with a 13.5% gain at the peak. It ended the window at 112.16. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.